Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
337.97
-2.84 (-0.83%)
At close: Nov 13, 2026, 4:00 PM EST
339.00
+1.03 (0.30%)
After-hours: Nov 13, 2026, 7:42 PM EST
CRL Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 26, 2026 | Dec '25 Dec 27, 2025 | Dec '24 Dec 28, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 25, 2021 |
| 3,977 | 4,015 | 4,050 | 4,129 | 3,976 | 3,540 | |
Revenue Growth | -1.16% | -0.85% | -1.92% | 3.86% | 12.31% | 21.07% |
Cost of Revenue | 2,581 | 2,611 | 2,642 | 2,600 | 2,508 | 2,203 |
Gross Profit | 1,396 | 1,405 | 1,408 | 1,529 | 1,468 | 1,337 |
Selling, General & Admin | 681.33 | 727.81 | 723.62 | 742.85 | 655.58 | 578.23 |
Amortization of Goodwill & Intangibles | 146.99 | 179.07 | 138.47 | 137.44 | 146.58 | 124.86 |
Operating Expenses | 828.32 | 906.88 | 862.09 | 880.29 | 802.15 | 703.08 |
Operating Income | 567.5 | 497.76 | 545.86 | 648.89 | 665.51 | 634.39 |
Interest Expense | -109.38 | -107.03 | -126.29 | -136.71 | -59.29 | -73.91 |
Interest & Investment Income | 4.04 | 4.94 | 8.58 | 5.2 | 0.78 | 0.65 |
Earnings From Equity Investments | 11.29 | -24.91 | -12.91 | 97.83 | -26.78 | -30.42 |
Currency Exchange Gain (Loss) | - | - | - | - | -46.53 | -31.83 |
Other Non Operating Income (Expenses) | 16.17 | 3.35 | 2.03 | 1.82 | -18.4 | 7.79 |
EBT Excluding Unusual Items | 489.62 | 374.11 | 417.26 | 617.03 | 515.3 | 506.67 |
Merger & Restructuring Charges | -107.93 | -101.01 | -108.49 | -34.78 | -15.71 | -45.96 |
Impairment of Goodwill | -165 | -165 | -215 | - | - | - |
Gain (Loss) on Sale of Assets | -176.92 | 3.38 | -0.66 | -0.96 | 123.41 | 20 |
Asset Writedown | -139.97 | -210.97 | - | - | - | - |
Pretax Income | -100.21 | -99.5 | 93.11 | 581.28 | 622.99 | 480.71 |
Income Tax Expense | -142.81 | 42.66 | 67.82 | 100.91 | 130.38 | 81.87 |
Earnings From Continuing Operations | 42.59 | -142.16 | 25.29 | 480.37 | 492.61 | 398.84 |
Net Income to Company | 42.59 | -142.16 | 25.29 | 480.37 | 492.61 | 398.84 |
Minority Interest in Earnings | -2.41 | -2.18 | -3.09 | -5.75 | -6.38 | -7.86 |
Net Income | 40.19 | -144.34 | 22.2 | 474.62 | 486.23 | 390.98 |
Preferred Dividends & Other Adjustments | - | - | 11.91 | - | - | - |
Net Income to Common | 40.19 | -144.34 | 10.3 | 474.62 | 486.23 | 390.98 |
Net Income Growth | - | - | -97.83% | -2.39% | 24.36% | 7.32% |
Shares Outstanding (Basic) | 48 | 50 | 51 | 51 | 51 | 50 |
Shares Outstanding (Diluted) | 49 | 50 | 52 | 51 | 51 | 51 |
Shares Change | -2.41% | -4.00% | 0.34% | 0.29% | -0.24% | 1.61% |
EPS (Basic) | 0.83 | -2.91 | 0.20 | 9.27 | 9.57 | 7.77 |
EPS (Diluted) | 0.83 | -2.91 | 0.20 | 9.22 | 9.48 | 7.60 |
EPS Growth | - | - | -97.83% | -2.74% | 24.74% | 5.56% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 26, 2026 | Dec '25 Dec 27, 2025 | Dec '24 Dec 28, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 25, 2021 |
Free Cash Flow | 399.63 | 518.49 | 501.61 | 365.37 | 294.91 | 532.03 |
Free Cash Flow Per Share | 8.18 | 10.46 | 9.72 | 7.10 | 5.75 | 10.35 |
Gross Margin | 35.10% | 34.98% | 34.76% | 37.03% | 36.91% | 37.78% |
Operating Margin | 14.27% | 12.40% | 13.48% | 15.71% | 16.74% | 17.92% |
Profit Margin | 1.01% | -3.60% | 0.25% | 11.49% | 12.23% | 11.04% |
Free Cash Flow Margin | 10.05% | 12.91% | 12.38% | 8.85% | 7.42% | 15.03% |
EBITDA | 909.38 | 876.57 | 870.5 | 963.02 | 969.38 | 899.93 |
EBITDA Margin | 22.87% | 21.83% | 21.49% | 23.32% | 24.38% | 25.42% |
D&A For EBITDA | 341.88 | 378.81 | 324.64 | 314.12 | 303.87 | 265.54 |
EBIT | 567.5 | 497.76 | 545.86 | 648.89 | 665.51 | 634.39 |
EBIT Margin | 14.27% | 12.40% | 13.48% | 15.71% | 16.74% | 17.92% |
Effective Tax Rate | - | - | 72.84% | 17.36% | 20.93% | 17.03% |
Revenue as Reported | 3,977 | 4,015 | 4,050 | 4,129 | 3,976 | 3,540 |